Platelet count correlates with stage and predicts survival in melanoma

Rachidi, Saleh; Kaur, Maneet; Lautenschlaeger, Tim; Li, Zihai

doi:10.1080/09537104.2019.1572879

Cited by 22 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombocytosis had been found as a worse prognostic predictor in different kind of cancer, include nasopharyngeal carcinoma [20], gynecologic malignancies [21], melanoma [22] and colorectal cancer [23].In RCC, thrombocytosis also could be regard as a prognostic indicator. Several study had already shown patients with preoperative thrombocytosis had a worse survival than those who without [24][25][26].Although none of these study had con rmed the thrombocytosis had worse prognosis in population of RCC with TT, previous study had found that bland thrombus in RCC with TT was associated with adverse survival [27].…”

Section: Discussionmentioning

confidence: 99%

Preoperative Anemia and Thrombocytosis Predict Adverse Prognosis in Non-Metastatic Renal Cell Carcinoma With Tumor Thrombus

Ruotao

Chuxiao

et al. 2020

Preprint

View full text Add to dashboard Cite

Objection: The aim of the study was to determine the prognostic value of preoperative blood parameters in patients with renal cell carcinoma (RCC) and tumor thrombus (TT) treated surgically.Method: we retrospectively analyzed 152 patients diagnosis with RCC and TT and treated surgically. Clinicopathologic data and blood parameter were obtained. Univariable and multivariable analysis using the Cox regression model were performed to determine risk factors that were associated with progression-free survival (PFS) and overall survival (OS). Kaplan-Meier curve and logistic regression were performed to analyze the risk factors.Results: Preoperative Hgb＜120g/L (HR=2.48, P=0.024) and lymph node metastasis (HR=3.98, P=0.032) were an independent prognostic factors associated with OS. Preoperative PLT≥300×109/L (HR=2.10, P=0.014) and lymph node metastasis (HR=3.42, P=0.021) were an independent prognostic factors associated with PFS. In Kaplan–Meier survival analysis, preoperative anemia had worse OS than without anemia (P=0.003) and thrombocytosis had worse PFS than without thrombocytosis (P=0.001). Preoperative anemia were associated with more symptomatic (P=0.009), surgical time≥6h (P=0.016), Blood loss≥1000ml (P=0.014), transfusion(P=0.012), higher thrombus level (III-IV) (P=0.004) and higher nuclear grade (III-IV) (P=0.002) while thrombocytosis were associated with more symptomatic (P=0.008) and higher nuclear grade (III-IV) (P=0.042)Conclusions: Preoperative anemia and thrombocytosis was associated with adverse prognosis in patients with non-metastatic RCC with TT. Both preoperative hemoglobin level and platelet count may be clinical useful for risk stratifying patients receiving operation for non-metastatic RCC with TT.

show abstract

Section: Discussionmentioning

confidence: 99%

Preoperative Anemia and Thrombocytosis Predict Adverse Prognosis in Non-Metastatic Renal Cell Carcinoma With Tumor Thrombus

Ruotao

Chuxiao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…We and others have demonstrated a clear correlation between platelet count and the presence of cancer [ 19 , 23 , 74 ]. Also, there is accumulating evidence that thrombocytosis (i.e., a platelet count above 400 × 10 9 platelets/L) is an independent predictor of poor prognosis in various types of cancer [ 19 ].…”

Section: Tumor Cells Influence Platelet Characteristicsmentioning

confidence: 94%

Platelets as messengers of early-stage cancer

Sabrkhany

Kuijpers

Egbrink

2021

Cancer Metastasis Rev

View full text Add to dashboard Cite

Platelets have an important role in tumor angiogenesis, growth, and metastasis. The reciprocal interaction between cancer and platelets results in changes of several platelet characteristics. It is becoming clear that analysis of these platelet features could offer a new strategy in the search for biomarkers of cancer. Here, we review the human studies in which platelet characteristics (e.g., count, volume, protein, and mRNA content) are investigated in early-stage cancer. The main focus of this paper is to evaluate which platelet features are suitable for the development of a blood test that could detect cancer in its early stages.

show abstract

“…Indeed, platelets may be loaded with nano-scale materials [40], as supported also by their phagocytosis properties, already demonstrated in a work of many decades ago [52]. Melanoma is not an exception and recent studies have highlighted the role and prognostic significance of platelets in the metastatic propensity of human melanoma [53][54][55][56]. A recent paper has shown the possibility to target an experimental melanoma with red blood cells and platelet membrane-coated ("ghost-cell" strategy) gold nanostars containing curcumin [57].…”

Section: Plateletsmentioning

confidence: 95%

Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma

Chillà

Margheri

Biagioni

et al. 2020

Cancers

View full text Add to dashboard Cite

Targeted and immune therapies have unquestionably improved the prognosis of melanoma patients. However the treatment of this neoplasm still requires approaches with a higher therapeutic index, in order to reduce shortcomings related to toxic effects and aspecific targeting. This means developing therapeutic tools derived with high affinity molecules for tumor components differentially expressed in melanoma cells with respect to their normal counterpart. Nanomedicine has sought to address this problem owing to the high modulability of nanoparticles. This approach exploits not only the enhanced permeability and retention effect typical of the tumor microenvironment (passive targeting), but also the use of specific “molecular antennas” that recognize some tumor-overexpressed molecules (active targeting). This line of research has given rise to the so-called “smart nanoparticles,” some of which have already passed the preclinical phase and are under clinical trials in melanoma patients. To further improve nanoparticles partition within tumors, for some years now a line of thought is exploiting the molecular systems that regulate the innate tumor-homing activity of platelets, granulocytes, monocytes/macrophages, stem cells, endothelial-colony-forming cells, and red blood cells loaded with nanoparticles. This new vision springs from the results obtained with some of these cells in regenerative medicine, an approach called “cell therapy.” This review takes into consideration the advantages of cell therapy as the only one capable of overcoming the limits of targeting imposed by the increased interstitial pressure of tumors.

show abstract

Platelet count correlates with stage and predicts survival in melanoma

Abstract: This paper includes 3 tables, 2 figures, 5 supplementary tables, and 21 references.

Cited by 22 publications

References 19 publications

Preoperative Anemia and Thrombocytosis Predict Adverse Prognosis in Non-Metastatic Renal Cell Carcinoma With Tumor Thrombus

Preoperative Anemia and Thrombocytosis Predict Adverse Prognosis in Non-Metastatic Renal Cell Carcinoma With Tumor Thrombus

Platelets as messengers of early-stage cancer

Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma

Contact Info

Product

Resources

About